Instrument Inactif

Communiqués GOLD SWAP OTC Bulletin Board

Actions

GDSW

US38074W1009

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

10/07	Les plus fortes baisses à la mi-séance	MT
10/07	Silo Pharma lance un placement privé pour lever jusqu'à 11,7 millions de dollars	MT

Communiqués

14/07	Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform	AQ
10/07	Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules	AQ
07/07	Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program	AQ
29/06	Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request	AQ
23/06	Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial	AQ
18/06	Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
07/05	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury	GL
29/04	Silo Pharma : PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	PU
29/04	Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	GL
22/04	Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents	GL
20/04	Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics	GL
06/04	Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy	GL
23/02	Silo Pharma Announces Share Buyback Program	GL
18/02	Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio	GL
30/12	Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15	GL
17/11	Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD	GL
29/10/25	Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain	GL
23/10/25	Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program	GL
09/10/25	Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth	AQ
08/10/25	Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company’s Commitment to Multi-Chain Growth	GL
06/10/25	Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)	GL
01/10/25	Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	GL
30/09/25	Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	GL
30/09/25	Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	AQ
29/09/25	Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management	GL